|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TMEM150A |
Gene summary for TMEM150A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TMEM150A | Gene ID | 129303 |
| Gene name | transmembrane protein 150A | |
| Gene Alias | TM6P1 | |
| Cytomap | 2p11.2 | |
| Gene Type | protein-coding | GO ID | GO:0006629 | UniProtAcc | Q86TG1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 129303 | TMEM150A | LZE24T | Human | Esophagus | ESCC | 1.19e-08 | 2.91e-01 | 0.0596 |
| 129303 | TMEM150A | P1T-E | Human | Esophagus | ESCC | 1.91e-02 | 1.46e-01 | 0.0875 |
| 129303 | TMEM150A | P2T-E | Human | Esophagus | ESCC | 2.28e-08 | 1.13e-01 | 0.1177 |
| 129303 | TMEM150A | P4T-E | Human | Esophagus | ESCC | 1.06e-09 | 1.19e-01 | 0.1323 |
| 129303 | TMEM150A | P5T-E | Human | Esophagus | ESCC | 5.13e-07 | 5.94e-02 | 0.1327 |
| 129303 | TMEM150A | P8T-E | Human | Esophagus | ESCC | 4.14e-11 | 1.28e-01 | 0.0889 |
| 129303 | TMEM150A | P9T-E | Human | Esophagus | ESCC | 1.95e-03 | 8.48e-02 | 0.1131 |
| 129303 | TMEM150A | P10T-E | Human | Esophagus | ESCC | 1.06e-12 | 7.48e-02 | 0.116 |
| 129303 | TMEM150A | P11T-E | Human | Esophagus | ESCC | 5.46e-14 | 4.57e-01 | 0.1426 |
| 129303 | TMEM150A | P12T-E | Human | Esophagus | ESCC | 7.30e-11 | 9.86e-02 | 0.1122 |
| 129303 | TMEM150A | P15T-E | Human | Esophagus | ESCC | 6.44e-04 | 1.12e-01 | 0.1149 |
| 129303 | TMEM150A | P16T-E | Human | Esophagus | ESCC | 3.65e-12 | 1.42e-01 | 0.1153 |
| 129303 | TMEM150A | P19T-E | Human | Esophagus | ESCC | 1.94e-04 | 2.88e-01 | 0.1662 |
| 129303 | TMEM150A | P20T-E | Human | Esophagus | ESCC | 5.82e-12 | 2.56e-01 | 0.1124 |
| 129303 | TMEM150A | P21T-E | Human | Esophagus | ESCC | 1.58e-10 | 2.66e-01 | 0.1617 |
| 129303 | TMEM150A | P22T-E | Human | Esophagus | ESCC | 5.44e-16 | 2.45e-01 | 0.1236 |
| 129303 | TMEM150A | P23T-E | Human | Esophagus | ESCC | 3.71e-27 | 6.21e-01 | 0.108 |
| 129303 | TMEM150A | P24T-E | Human | Esophagus | ESCC | 4.54e-18 | 1.63e-01 | 0.1287 |
| 129303 | TMEM150A | P26T-E | Human | Esophagus | ESCC | 2.33e-14 | 1.76e-01 | 0.1276 |
| 129303 | TMEM150A | P27T-E | Human | Esophagus | ESCC | 2.61e-05 | 6.90e-02 | 0.1055 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0072659110 | Esophagus | ESCC | protein localization to plasma membrane | 193/8552 | 284/18723 | 1.95e-14 | 1.03e-12 | 193 |
| GO:199077819 | Esophagus | ESCC | protein localization to cell periphery | 217/8552 | 333/18723 | 4.08e-13 | 1.88e-11 | 217 |
| GO:00086544 | Esophagus | ESCC | phospholipid biosynthetic process | 162/8552 | 253/18723 | 2.59e-09 | 5.73e-08 | 162 |
| GO:00464744 | Esophagus | ESCC | glycerophospholipid biosynthetic process | 135/8552 | 211/18723 | 5.75e-08 | 1.02e-06 | 135 |
| GO:00450175 | Esophagus | ESCC | glycerolipid biosynthetic process | 154/8552 | 252/18723 | 5.20e-07 | 6.96e-06 | 154 |
| GO:00066446 | Esophagus | ESCC | phospholipid metabolic process | 218/8552 | 383/18723 | 5.37e-06 | 5.59e-05 | 218 |
| GO:00066505 | Esophagus | ESCC | glycerophospholipid metabolic process | 174/8552 | 306/18723 | 4.92e-05 | 3.85e-04 | 174 |
| GO:00464864 | Esophagus | ESCC | glycerolipid metabolic process | 211/8552 | 392/18723 | 6.51e-04 | 3.46e-03 | 211 |
| GO:00066611 | Esophagus | ESCC | phosphatidylinositol biosynthetic process | 73/8552 | 131/18723 | 1.31e-02 | 4.28e-02 | 73 |
| GO:199077811 | Liver | Cirrhotic | protein localization to cell periphery | 135/4634 | 333/18723 | 1.18e-10 | 6.21e-09 | 135 |
| GO:007265911 | Liver | Cirrhotic | protein localization to plasma membrane | 119/4634 | 284/18723 | 1.30e-10 | 6.80e-09 | 119 |
| GO:007265921 | Liver | HCC | protein localization to plasma membrane | 177/7958 | 284/18723 | 1.02e-11 | 4.18e-10 | 177 |
| GO:199077821 | Liver | HCC | protein localization to cell periphery | 200/7958 | 333/18723 | 6.07e-11 | 2.23e-09 | 200 |
| GO:00086542 | Liver | HCC | phospholipid biosynthetic process | 150/7958 | 253/18723 | 4.77e-08 | 1.03e-06 | 150 |
| GO:00066444 | Liver | HCC | phospholipid metabolic process | 214/7958 | 383/18723 | 7.25e-08 | 1.48e-06 | 214 |
| GO:004648611 | Liver | HCC | glycerolipid metabolic process | 215/7958 | 392/18723 | 4.54e-07 | 7.49e-06 | 215 |
| GO:004501711 | Liver | HCC | glycerolipid biosynthetic process | 143/7958 | 252/18723 | 3.27e-06 | 4.31e-05 | 143 |
| GO:00066504 | Liver | HCC | glycerophospholipid metabolic process | 168/7958 | 306/18723 | 7.27e-06 | 8.62e-05 | 168 |
| GO:004647411 | Liver | HCC | glycerophospholipid biosynthetic process | 121/7958 | 211/18723 | 9.12e-06 | 1.06e-04 | 121 |
| GO:0006661 | Liver | HCC | phosphatidylinositol biosynthetic process | 69/7958 | 131/18723 | 1.19e-02 | 4.35e-02 | 69 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TMEM150A | insertion | Frame_Shift_Ins | novel | c.52_53insAGAC | p.Gly18GlufsTer31 | p.G18Efs*31 | Q86TG1 | protein_coding | TCGA-A7-A0CG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| TMEM150A | SNV | Missense_Mutation | c.148N>A | p.Glu50Lys | p.E50K | Q86TG1 | protein_coding | tolerated(0.88) | benign(0) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| TMEM150A | SNV | Missense_Mutation | c.493G>T | p.Gly165Trp | p.G165W | Q86TG1 | protein_coding | tolerated(0.1) | possibly_damaging(0.855) | TCGA-AA-3833-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TMEM150A | SNV | Missense_Mutation | c.593N>G | p.His198Arg | p.H198R | Q86TG1 | protein_coding | deleterious(0.03) | benign(0.193) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TMEM150A | SNV | Missense_Mutation | novel | c.553N>A | p.Ala185Thr | p.A185T | Q86TG1 | protein_coding | deleterious(0.01) | possibly_damaging(0.892) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| TMEM150A | SNV | Missense_Mutation | novel | c.23C>A | p.Pro8His | p.P8H | Q86TG1 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TMEM150A | SNV | Missense_Mutation | c.806C>T | p.Ala269Val | p.A269V | Q86TG1 | protein_coding | deleterious_low_confidence(0.05) | probably_damaging(0.941) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TMEM150A | SNV | Missense_Mutation | novel | c.449N>T | p.Ala150Val | p.A150V | Q86TG1 | protein_coding | deleterious(0.03) | benign(0.419) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TMEM150A | SNV | Missense_Mutation | novel | c.287N>C | p.Leu96Pro | p.L96P | Q86TG1 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TMEM150A | SNV | Missense_Mutation | c.533N>A | p.Arg178Gln | p.R178Q | Q86TG1 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |